ASCO Gastrointestinal Cancers Symposium

Coverage from the ASCO Gastrointestinal Cancers Symposium.

Minimally Invasive Procedure Combined with Lenvima and Checkpoint Blockade Shows Promise in Unresectable Liver Cancer

January 21st 2022

The use of a minimally invasive procedure — known as trans-arterial chemoembolization — plus Lenvima and a PD-1 checkpoint blockade drug proved to be safe and efficacious in patients with unresectable advanced liver cancer.

Enhertu Linked to Sustained Survival Benefit in Gastroesophageal, Gastric Cancer Subset

January 21st 2022

The use of Enhertu was associated with a reduction in the risk of death compared with standard chemotherapy in certain patients with gastroesophageal and gastric cancer.

Novel Therapy Shows Promise in Liver Cancer Subset, May Address ‘Urgent Need for New Therapies’

January 21st 2021

“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.

Inlyta-Synthetic Hormone Combo Fails to Significantly Improve Survival Outcome in Pancreatic Neuroendocrine Tumors

January 20th 2021

The combination of Inlyta (axitinib) and the synthetic hormone octreotide acetate failed to significantly improve progression-free survival, compared to placebo with the synthetic hormone. However, the results indicated the Inlyta-based combination did improve disease response in patients versus the placebo-based combination.

Avastin-Lonsurf Combo Improves Survival in Patients with Metastatic Colorectal Cancer Ineligible for Standard Chemo

January 19th 2021

In the final analysis of the phase 2 TASCO1 trial, patients within the Lonsurf and Avastin arm reached a median overall survival of 22.31 months compared with 17.67 months in the Xeloda and Avastin arm.

Tecentriq-Avastin Combo Continues to Show Improved Survival Benefit in Patients with Advanced Liver Cancer

January 19th 2021

“This is the longest survival seen in a phase 3 study of advanced liver cancer,” lead study author Dr. Richard S. Finn, of the UCLA Jonsson Comprehensive Cancer Center, said in a virtual presentation of the data.

Advanced-Stage Rare Type of Gastrointestinal Cancer More Common in Men, Associated with ‘Excellent’ 5-Year Survival Rates

January 19th 2021

The data in the study presented at the ASCO Gastrointestinal Cancers Symposium demonstrated that while rare, stage 4 gastrointestinal stromal tumors often spread to the liver.

Novel Artificial Intelligence Tool May Help Patients with Cancer Find, Understand Clinical Trials

January 18th 2021

A group of patients with gastrointestinal cancers reported that a novel artificial intelligence-based search tool made it easier for them to find and understand cancer clinical trials. The tool, according to study authors, would not only help with trial accrual, but could also help improve trial diversity.

Counseling, Targeted Interventions Needed to Improve Health-Related Quality of Life in Young Colon Cancer Survivors

January 17th 2021

The researchers concluded that the overall low health-related quality of life scores for young CRC survivors in the categories of social and functional well-being should be targeted by appropriate methods, which could include counseling and quality of life interventions.

Alleviating Pandemic-Related Anxiety Over Returning to the Clinic for Clinical Trials

January 16th 2021

In an interview with CURE®, expert Martha Raymond explains the importance of clinical trials during the COVID-19 pandemic and how clinicians must find a way to help ease patients anxieties as they return to the clinic.